Table 2.
Quality measure | Hudson Valley | National benchmark | ||||
---|---|---|---|---|---|---|
Performance* | ||||||
N† | Overall | Paper | EHR | p-value‡ | ||
Diabetes—eye visit | 86 | 34.1 % | 35.1 % | 32.7 % | 0.28 | 56.5 % |
Diabetes—HgbA1c testing | 86 | 86.7 % | 84.2 % | 90.1 % | < 0.01 | 89.0 % |
Diabetes—LDL testing | 86 | 86.2 % | 85.1 % | 87.6 % | 0.26 | 84.8 % |
Diabetes—nephropathy screening | 86 | 66.3 % | 64.8 % | 68.2 % | 0.33 | 82.4 % |
Breast cancer screening | 358 | 76.1 % | 74.2 % | 78.6 % | < 0.001 | 70.2 % |
Chlamydia screening | 27 | 59.7 % | 53.0 % | 65.8 % | 0.02 | 41.7 % |
Colorectal cancer screening | 391 | 49.4 % | 48.0 % | 51.3 % | 0.01 | 58.6 % |
Appropriate testing for children with pharyngitis | 28 | 65.9 % | 74.2 % | 52.9 % | 0.05 | 75.6 % |
Appropriate treatment for children with upper respiratory infection | 55 | 91.5 % | 93.0 % | 90.0 % | 0.19 | 83.9 % |
EHR electronic health record. Hgb A1c hemoglobin A1c. LDL low-density lipoprotein
* Performance is first calculated as the proportion of a provider’s patients who received the recommended intervention and then averaged across the providers in the stated group
† Of the 466 physicians, 315 contributed data for only breast cancer and colorectal cancer screening
‡ p-values were calculated with t-tests comparing the paper and EHR groups